FDA Inspection
Re-Gen Active Lab IncRe-Gen Active Lab Inc – FDA Inspection, Sep 21, 2023
Record Details
This FDA Inspection record concerns Re-Gen Active Lab Inc, with an inspection on September 21, 2023, issued by the Dallas District Office.
- Company
- Re-Gen Active Lab Inc
- Inspection Date
- September 21, 2023
View Company Profile
ID · 8f9f7775-7ffe-42d0-b561-2c784b4c2ada
Inspection Facts
- Inspection number
- 1218428
- FDA center
- Biologics
- Outcome
- Form 483 issued
FDA Citations
13- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.113(b)Validation lacking for sterile drug products
- 21 CFR 211.142(b)Storage under appropriate conditions
- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.166(a)Lack of written stability program
- 21 CFR 211.188(b)Batch production and Batch Control Record Requirements
- 21 CFR 211.192Quality control unit review of records
- 21 CFR 211.42(c)(8)Released Drug Products Area
- 21 CFR 211.46(b)Equipment for Environmental Control
- 21 CFR 211.67(b)Written procedures not established/followed
Showing 10 of 13 citations.
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Re-Gen Active Lab Inc
1| Date | Classification | Office | Project area |
|---|---|---|---|
| July 28, 2021 | OAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Re-Gen Active Lab Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.